published meta-analysis   sensitivity analysis   studies

remdesivir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsGS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] 0.65[0.21; 2.01]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable clinical improvementdetailed resultsGS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] 1.38[0.98; 1.95]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020230%796moderatenot evaluable clinical improvement (14-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] 1.57[1.15; 2.16]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable clinical improvement (28-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] 1.81[1.19; 2.76]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable clinical improvement (7-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.53 [1.01; 2.34] 1.25[0.84; 1.85]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020246%784moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-19 05:50 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 510 - roots T: 290